New issues in systemic therapy for ovarian cancer

Research output: Contribution to journalArticle

Abstract

Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.

Original languageEnglish (US)
Pages (from-to)690-693
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number5 SUPPL.
DOIs
StatePublished - May 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'New issues in systemic therapy for ovarian cancer'. Together they form a unique fingerprint.

  • Cite this